Search

Pomalidomide prolongs survival in refractory myeloma patients

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…

Read more

Revising the ICH Guidelines on Clinical Trials

The EHA delegation to the ICH meeting: from left to right, Professors Christian Gisselbrecht, Steven Le Gouill and Martin Dreyling. Clinical trials and drug development have become more complex over the years.

Read more

Lighting the Flame Journal Club

A learning and connecting hematology experience led by alumni of the Lighting the Flame program. The Lighting the Flame Journal Club is an online group that's open to all members of the Lighting the Flame community.

Read more

Abstract & travel grant submission

Abstract submission is closed

Abstract procedurePlease note that the submission of an abstract constitutes a formal commitment by the presenting author to present the abstract (if accepted) orally or as a poster in the session at the time assigned by the…

Read more

SWG Educational Activities

2023 meetingsThe following EHA-SWG meetings took place in the past calendar year:

54th General Assembly of ERIC members at ELN Symposium 2023
Mannheim, Germany
April 18, 2023

ERIC/Brazilian CLL Group workshop on biomarkers in CLL
Brasilia, Brazil
May 25–26, 2023

55th General Assembly of ERIC members at…

Read more

Adult Acute Lymphoblastic Leukemia

The Specialized Working Group on Adult Acute Lymphoblastic Leukemia consists mainly of the members of the EWALL group, which is the European Working Group for Adult ALL. This includes the leaders of the national ALL study groups in Europe.

Read more

Board

The EHA Board is the governing body of the association and deals with issues of policy. The Board sets the goals and objectives of the association in conformity with the EHA's statutes.

Read more